Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX

Quantinno Capital Management LP raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 178.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,744 shares of the biopharmaceutical company’s stock after buying an additional 42,158 shares during the period. Quantinno Capital Management LP owned 0.08% of Celldex Therapeutics worth $2,085,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its stake in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after purchasing an additional 680 shares in the last quarter. ProShare Advisors LLC increased its holdings in Celldex Therapeutics by 6.9% in the 4th quarter. ProShare Advisors LLC now owns 11,973 shares of the biopharmaceutical company’s stock worth $325,000 after purchasing an additional 773 shares in the last quarter. Panagora Asset Management Inc. raised its position in Celldex Therapeutics by 7.5% in the fourth quarter. Panagora Asset Management Inc. now owns 21,856 shares of the biopharmaceutical company’s stock valued at $594,000 after purchasing an additional 1,522 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in Celldex Therapeutics in the third quarter valued at about $42,000.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Wells Fargo & Company boosted their price target on Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Barclays raised their price objective on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a report on Friday. Wall Street Zen upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. UBS Group boosted their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $55.46.

Celldex Therapeutics Price Performance

Shares of CLDX stock opened at $42.97 on Tuesday. The stock has a market capitalization of $3.37 billion, a PE ratio of -9.88 and a beta of 0.87. The business’s 50 day simple moving average is $35.45 and its 200 day simple moving average is $31.70. Celldex Therapeutics, Inc. has a one year low of $19.72 and a one year high of $43.21.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.73 million. As a group, research analysts expect that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.